This report was recently updated on November 18 2024 with the latest and most recent
market numbers
Global Biomaterial-based Vaccines Market Size, Trends & Analysis - Forecasts to 2029 By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines, and Transdermal Vaccines), By Type of Biomaterial (Lipid-based Vaccines, Polymer-based Vaccines, Protein-based Vaccines, Nanoparticle-based Vaccines, and Others), and By Region (North America, Asia Pacific, Central & South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global biomaterial-based vaccines market is analyzed to grow at a CAGR of 17.7% during the forecast period from 2024 to 2029. Biomaterials like proteins, peptides, lipids, carbohydrates, and nucleic acids, among others, are utilized for vaccine delivery and enhancement. These biomaterials often play crucial roles in improving vaccine stability and immunogenicity and targeting specific immune responses.
The market is driven by technological advancements and increasing disease burden. Continuous innovations in biomaterials and vaccine delivery systems enhance the efficacy, safety, and scalability of biomaterial-based vaccines, driving market expansion. Rising incidence of infectious diseases and the emergence of novel pathogens worldwide create a growing demand for effective vaccines, prompting investment in biomaterial-based vaccine development. The versatility of biomaterials enables their utilization in diverse vaccine formulations, including those targeting infectious diseases, cancer, and autoimmune disorders, presenting opportunities for market expansion into new therapeutic areas.
Stringent regulatory requirements and lengthy approval processes pose barriers to market entry for biomaterial-based vaccines, leading to delays in product commercialization and adoption.
Based on route of administration, the market is segmented into injectable vaccines, oral vaccines, nasal vaccines, and transdermal vaccines. The injectable vaccines segment is expected to hold the largest share of the market during the forecast period. Injectable vaccines have been widely used for decades and are well-established in vaccination programs worldwide. They offer precise dosing, reliable efficacy, and robust immune responses, making them the preferred choice for many vaccines, especially those targeting systemic infections or diseases.
The nasal vaccines segment is projected to grow fastest during the forecast period. Nasal vaccines offer several advantages, including ease of administration, enhanced mucosal immune response, and potential needle-free vaccination, making them attractive for both patients and healthcare providers. Additionally, nasal vaccines hold promise for preventing respiratory infections, including influenza and COVID-19, further driving their growth.
Based on type of biomaterial, the market is segmented into lipid-based vaccines, polymer-based vaccines, protein-based vaccines, nanoparticle-based vaccines, and others. The protein-based vaccines segment is expected to hold the largest share of the market during the forecast period. Proteins are widely recognized as effective vaccine components due to their ability to elicit strong immune responses and safety profiles. Many conventional vaccines, such as those for hepatitis B, HPV, and influenza, are protein-based formulations, contributing to this segment's established dominance in the biomaterial-based vaccines market.
The nanoparticle-based vaccines segment is projected to grow fastest during the forecast period. It can be attributed to their versatility and efficacy in vaccine delivery and immune stimulation. Nanoparticle-based vaccines offer advantages such as enhanced antigen presentation, controlled release kinetics, and targeted delivery to specific cells or tissues, contributing to their rapid adoption and development in the market.
North America is analyzed to be the largest region in the global biomaterial-based vaccines market during the forecast period. The growth is due to its robust research infrastructure, high healthcare expenditure, and strong government support for vaccine development initiatives. Additionally, a rising prevalence of infectious diseases and a growing emphasis on preventive healthcare further contribute to the region's dominance in this market.
Asia Pacific is analyzed to be the fastest-growing region in the global biomaterial-based vaccines market during the forecast period. Rising healthcare spending in countries like China, India, and Japan fuels demand for advanced healthcare solutions, including biomaterial-based vaccines. Rapid economic growth in countries across the region supports increased investment in healthcare infrastructure and research, fostering vaccine development. With a growing burden of infectious diseases and increasing awareness of preventive healthcare measures, there is a heightened demand for effective vaccines, driving the growth of the biomaterial-based vaccines market in the Asia Pacific. The region experiences significant advancements in biotechnology and nanotechnology, facilitating the development of innovative vaccine delivery systems based on biomaterials.
Wyss Institute, Creative Biolabs, Novavax, Sanofi, AstraZeneca, Evonik, Merck, Sigma-Aldrich, SK bioscience, and Precision NanoSystems, among others, are some of the key players operating in the global market.
Please note: This is not an exhaustive list of companies profiled in the report.
In November 2023, Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older.
In October 2023, Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, announced a development and commercialization agreement with Sanofi for Janssen’s extraintestinal pathogenic Escherichia coli (ExPEC) investigational vaccine program.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL BIOMATERIAL-BASED VACCINES MARKET, BY ROUTE OF ADMINISTRATION
4.1 Introduction
4.2 Biomaterial-based Vaccines Market: Route of Administration Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Injectable vaccines
4.4.1 Injectable Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Oral Vaccines
4.5.1 Oral Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Nasal Vaccines
4.6.1 Nasal Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
4.7 Transdermal Vaccines
4.7.1 Transdermal Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL BIOMATERIAL-BASED VACCINES MARKET, BY TYPE OF BIOMATERIAL
5.1 Introduction
5.2 Biomaterial-based Vaccines Market: Type of Biomaterial Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Lipid-based Vaccines
5.4.1 Lipid-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Polymer-based Vaccines
5.5.1 Polymer-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 Protein-based Vaccines
5.6.1 Protein-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
5.7 Nanoparticle-based Vaccines
5.7.1 Nanoparticle-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
5.8 Others
5.8.1 Others Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL BIOMATERIAL-BASED VACCINES MARKET, BY REGION
6.1 Introduction
6.2 North America Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.1 By Route of Administration
6.2.2 By Type of Biomaterial
6.2.3 By Country
6.2.3.1 U.S. Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.1.1 By Route of Administration
6.2.3.1.2 By Type of Biomaterial
6.2.3.2 Canada Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.2.1 By Route of Administration
6.2.3.2.2 By Type of Biomaterial
6.2.3.3 Mexico Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.3.1 By Route of Administration
6.2.3.3.2 By Type of Biomaterial
6.3 Europe Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.1 By Route of Administration
6.3.2 By Type of Biomaterial
6.3.3 By Country
6.3.3.1 Germany Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.1.1 By Route of Administration
6.3.3.1.2 By Type of Biomaterial
6.3.3.2 U.K. Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.2.1 By Route of Administration
6.3.3.2.2 By Type of Biomaterial
6.3.3.3 France Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.3.1 By Route of Administration
6.3.3.3.2 By Type of Biomaterial
6.3.3.4 Italy Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.4.1 By Route of Administration
6.3.3.4.2 By Type of Biomaterial
6.3.3.5 Spain Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.5.1 By Route of Administration
6.3.3.5.2 By Type of Biomaterial
6.3.3.6 Netherlands Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Route of Administration
6.3.3.6.2 By Type of Biomaterial
6.3.3.7 Rest of Europe Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Route of Administration
6.3.3.6.2 By Type of Biomaterial
6.4 Asia Pacific Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.1 By Route of Administration
6.4.2 By Type of Biomaterial
6.4.3 By Country
6.4.3.1 China Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.1.1 By Route of Administration
6.4.3.1.2 By Type of Biomaterial
6.4.3.2 Japan Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.2.1 By Route of Administration
6.4.3.2.2 By Type of Biomaterial
6.4.3.3 India Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.3.1 By Route of Administration
6.4.3.3.2 By Type of Biomaterial
6.4.3.4 South Korea Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.4.1 By Route of Administration
6.4.3.4.2 By Type of Biomaterial
6.4.3.5 Singapore Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.5.1 By Route of Administration
6.4.3.5.2 By Type of Biomaterial
6.4.3.6 Malaysia Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Route of Administration
6.4.3.6.2 By Type of Biomaterial
6.4.3.7 Thailand Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Route of Administration
6.4.3.6.2 By Type of Biomaterial
6.4.3.8 Indonesia Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.7.1 By Route of Administration
6.4.3.7.2 By Type of Biomaterial
6.4.3.9 Vietnam Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.8.1 By Route of Administration
6.4.3.8.2 By Type of Biomaterial
6.4.3.10 Taiwan Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.10.1 By Route of Administration
6.4.3.10.2 By Type of Biomaterial
6.4.3.11 Rest of Asia Pacific Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.11.1 By Route of Administration
6.4.3.11.2 By Type of Biomaterial
6.5 Middle East and Africa Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.1 By Route of Administration
6.5.2 By Type of Biomaterial
6.5.3 By Country
6.5.3.1 Saudi Arabia Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.1.1 By Route of Administration
6.5.3.1.2 By Type of Biomaterial
6.5.3.2 U.A.E. Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.2.1 By Route of Administration
6.5.3.2.2 By Type of Biomaterial
6.5.3.3 Israel Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.3.1 By Route of Administration
6.5.3.3.2 By Type of Biomaterial
6.5.3.4 South Africa Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.4.1 By Route of Administration
6.5.3.4.2 By Type of Biomaterial
6.5.3.5 Rest of Middle East and Africa Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.5.1 By Route of Administration
6.5.3.5.2 By Type of Biomaterial
6.6 Central & South America Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.1 By Route of Administration
6.6.2 By Type of Biomaterial
6.6.3 By Country
6.6.3.1 Brazil Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.1.1 By Route of Administration
6.6.3.1.2 By Type of Biomaterial
6.6.3.2 Argentina Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.2.1 By Route of Administration
6.6.3.2.2 By Type of Biomaterial
6.6.3.3 Chile Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Route of Administration
6.6.3.3.2 By Type of Biomaterial
6.6.3.3 Rest of Central & South America Biomaterial-based Vaccines Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Route of Administration
6.6.3.3.2 By Type of Biomaterial
7 COMPETITIVE LANDCAPE
7.1 Company Market Share Analysis
7.2 Four Quadrant Positioning Matrix
7.2.1 Market Leaders
7.2.2 Market Visionaries
7.2.3 Market Challengers
7.2.4 Niche Market Players
7.3 Vendor Landscape
7.3.1 North America
7.3.2 Europe
7.3.3 Asia Pacific
7.3.4 Rest of the World
7.4 Company Profiles
7.4.1 Wyss Institute
7.4.1.1 Business Description & Financial Analysis
7.4.1.2 SWOT Analysis
7.4.1.3 Products & Services Offered
7.4.1.4 Strategic Alliances between Business Partners
7.4.2 Creative Biolabs
7.4.2.1 Business Description & Financial Analysis
7.4.2.2 SWOT Analysis
7.4.2.3 Products & Services Offered
7.4.2.4 Strategic Alliances between Business Partners
7.4.3 Novavax
7.4.3.1 Business Description & Financial Analysis
7.4.3.2 SWOT Analysis
7.4.3.3 Products & Services Offered
7.4.3.4 Strategic Alliances between Business Partners
7.4.4 Sanofi
7.4.4.1 Business Description & Financial Analysis
7.4.4.2 SWOT Analysis
7.4.4.3 Products & Services Offered
7.4.4.4 Strategic Alliances between Business Partners
7.4.5 AstraZeneca
7.4.5.1 Business Description & Financial Analysis
7.4.5.2 SWOT Analysis
7.4.5.3 Products & Services Offered
7.4.5.4 Strategic Alliances between Business Partners
7.4.6 EVONIK
7.4.6.1 Business Description & Financial Analysis
7.4.6.2 SWOT Analysis
7.4.6.3 Products & Services Offered
7.4.6.4 Strategic Alliances between Business Partners
7.4.7 Merck
7.4.7.1 Business Description & Financial Analysis
7.4.7.2 SWOT Analysis
7.4.7.3 Products & Services Offered
7.4.7.4 Strategic Alliances between Business Partners
7.4.8 Sigma-Aldrich
7.4.8.1 Business Description & Financial Analysis
7.4.8.2 SWOT Analysis
7.4.8.3 Products & Services Offered
7.4.8.4 Strategic Alliances between Business Partners
7.4.9 SK Bioscience
7.4.9.1 Business Description & Financial Analysis
7.4.9.2 SWOT Analysis
7.4.9.3 Products & Services Offered
7.4.9.4 Strategic Alliances between Business Partners
7.4.10 Precision NanoSystems
7.4.10.1 Business Description & Financial Analysis
7.4.10.2 SWOT Analysis
7.4.10.3 Products & Services Offered
7.4.10.4 Strategic Alliances between Business Partners
7.4.11 Other Companies
7.4.11.1 Business Description & Financial Analysis
7.4.11.2 SWOT Analysis
7.4.11.3 Products & Services Offered
7.4.11.4 Strategic Alliances between Business Partners
8 RESEARCH METHODOLOGY
8.1 Market Introduction
8.1.1 Market Definition
8.1.2 Market Scope & Segmentation
8.2 Information Procurement
8.2.1 Secondary Research
8.2.1.1 Purchased Databases
8.2.1.2 GMEs Internal Data Repository
8.2.1.3 Secondary Resources & Third Party Perspectives
8.2.1.4 Company Information Sources
8.2.2 Primary Research
8.2.2.1 Various Types of Respondents for Primary Interviews
8.2.2.2 Number of Interviews Conducted throughout the Research Process
8.2.2.3 Primary Stakeholders
8.2.2.4 Discussion Guide for Primary Participants
8.2.3 Expert Panels
8.2.3.1 Expert Panels Across 30+ Industry
8.2.4 Paid Local Experts
8.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
8.3 Market Estimation
8.3.1 Top-Down Approach
8.3.1.1 Macro-Economic Indicators Considered
8.3.1.2 Micro-Economic Indicators Considered
8.3.2 Bottom Up Approach
8.3.2.1 Company Share Analysis Approach
8.3.2.2 Estimation of Potential Product Sales
8.4 Data Triangulation
8.4.1 Data Collection
8.4.2 Time Series, Cross Sectional & Panel Data Analysis
8.4.3 Cluster Analysis
8.5 Analysis and Output
8.5.1 Inhouse AI Based Real Time Analytics Tool
8.5.2 Output From Desk & Primary Research
8.6 Research Assumptions & Limitations
8.6.1 Research Assumptions
8.6.2 Research Limitations
LIST OF TABLES
1 Global Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
2 Injectable Vaccines Market, By Region, 2021-2029 (USD Million)
3 Oral Vaccines Market, By Region, 2021-2029 (USD Million)
4 Nasal Vaccines Market, By Region, 2021-2029 (USD Million)
5 Transdermal Vaccines Market, By Region, 2021-2029 (USD Million)
6 Global Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
7 Lipid-based Vaccines Market, By Region, 2021-2029 (USD Million)
8 Polymer-based Vaccines Market, By Region, 2021-2029 (USD Million)
9 Protein-based Vaccines Market, By Region, 2021-2029 (USD Million)
10 Nanoparticle-based Vaccines Market, By Region, 2021-2029 (USD Million)
11 Others Market, By Region, 2021-2029 (USD Million)
12 Regional Analysis, 2021-2029 (USD Million)
13 North America Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
14 North America Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
15 North America Biomaterial-based Vaccines Market, By Country, 2021-2029 (USD Million)
16 U.S. Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
17 U.S. Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
18 Canada Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
19 Canada Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
20 Mexico Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
21 Mexico Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
22 Europe Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
23 Europe Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
24 Europe Biomaterial-based Vaccines Market, By Country, 2021-2029 (USD Million)
25 Germany Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
26 Germany Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
27 U.K. Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
28 U.K. Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
29 France Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
30 France Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
31 Italy Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
32 Italy Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
33 Spain Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
34 Spain Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
35 Netherlands Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
36 Netherlands Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
37 Rest Of Europe Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
38 Rest Of Europe Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
39 Asia Pacific Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
40 Asia Pacific Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
41 Asia Pacific Biomaterial-based Vaccines Market, By Country, 2021-2029 (USD Million)
42 China Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
43 China Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
44 Japan Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
45 Japan Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
46 India Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
47 India Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
48 South Korea Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
49 South Korea Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
50 Singapore Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
51 Singapore Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
52 Thailand Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
53 Thailand Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
54 Malaysia Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
55 Malaysia Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
56 Indonesia Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
57 Indonesia Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
58 Vietnam Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
59 Vietnam Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
60 Taiwan Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
61 Taiwan Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
62 Rest of APAC Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
63 Rest of APAC Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
64 Middle East and Africa Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
65 Middle East and Africa Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
66 Middle East and Africa Biomaterial-based Vaccines Market, By country, 2021-2029 (USD Million)
67 Saudi Arabia Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
68 Saudi Arabia Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
69 UAE Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
70 UAE Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
71 Israel Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
72 Israel Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
73 South Africa Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
74 South Africa Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
75 Rest Of Middle East and Africa Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
76 Rest Of Middle East and Africa Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
77 Central & South America Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
78 Central & South America Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
79 Central & South America Biomaterial-based Vaccines Market, By Country, 2021-2029 (USD Million)
80 Brazil Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
81 Brazil Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
82 Chile Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
83 Chile Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
84 Argentina Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
85 Argentina Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
86 Rest Of Central & South America Biomaterial-based Vaccines Market, By Route of Administration, 2021-2029 (USD Million)
87 Rest Of Central & South America Biomaterial-based Vaccines Market, By Type of Biomaterial, 2021-2029 (USD Million)
88 Wyss Institute: Products & Services Offering
89 Creative Biolabs: Products & Services Offering
90 Novavax: Products & Services Offering
91 Sanofi: Products & Services Offering
92 AstraZeneca: Products & Services Offering
93 EVONIK: Products & Services Offering
94 Merck: Products & Services Offering
95 Sigma-Aldrich: Products & Services Offering
96 SK Bioscience: Products & Services Offering
97 Precision NanoSystems: Products & Services Offering
98 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Biomaterial-based Vaccines Market Overview
2 Global Biomaterial-based Vaccines Market Value From 2021-2029 (USD Million)
3 Global Biomaterial-based Vaccines Market Share, By Route of Administration (2023)
4 Global Biomaterial-based Vaccines Market Share, By Type of Biomaterial (2023)
5 Global Biomaterial-based Vaccines Market, By Region (Asia Pacific Market)
6 Technological Trends In Global Biomaterial-based Vaccines Market
7 Four Quadrant Competitor Positioning Matrix
8 Impact Of Macro & Micro Indicators On The Market
9 Impact Of Key Drivers On The Global Biomaterial-based Vaccines Market
10 Impact Of Challenges On The Global Biomaterial-based Vaccines Market
11 Porter’s Five Forces Analysis
12 Global Biomaterial-based Vaccines Market: By Route of Administration Scope Key Takeaways
13 Global Biomaterial-based Vaccines Market, By Route of Administration Segment: Revenue Growth Analysis
14 Injectable Vaccines Market, By Region, 2021-2029 (USD Million)
15 Oral Vaccines Market, By Region, 2021-2029 (USD Million)
16 Nasal Vaccines Market, By Region, 2021-2029 (USD Million)
17 Transdermal Vaccines Market, By Region, 2021-2029 (USD Million)
18 Global Biomaterial-based Vaccines Market: By Type of Biomaterial Scope Key Takeaways
19 Global Biomaterial-based Vaccines Market, By Type of Biomaterial Segment: Revenue Growth Analysis
20 Lipid-based Vaccines Market, By Region, 2021-2029 (USD Million)
21 Polymer-based Vaccines Market, By Region, 2021-2029 (USD Million)
22 Protein-based Vaccines Market, By Region, 2021-2029 (USD Million)
23 Nanoparticle-based Vaccines Market, By Region, 2021-2029 (USD Million)
24 Others Market, By Region, 2021-2029 (USD Million)
25 Regional Segment: Revenue Growth Analysis
26 Global Biomaterial-based Vaccines Market: Regional Analysis
27 North America Biomaterial-based Vaccines Market Overview
28 North America Biomaterial-based Vaccines Market, By Route of Administration
29 North America Biomaterial-based Vaccines Market, By Type of Biomaterial
30 North America Biomaterial-based Vaccines Market, By Country
31 U.S. Biomaterial-based Vaccines Market, By Route of Administration
32 U.S. Biomaterial-based Vaccines Market, By Type of Biomaterial
33 Canada Biomaterial-based Vaccines Market, By Route of Administration
34 Canada Biomaterial-based Vaccines Market, By Type of Biomaterial
35 Mexico Biomaterial-based Vaccines Market, By Route of Administration
36 Mexico Biomaterial-based Vaccines Market, By Type of Biomaterial
37 Four Quadrant Positioning Matrix
38 Company Market Share Analysis
39 Wyss Institute: Company Snapshot
40 Wyss Institute: SWOT Analysis
41 Wyss Institute: Geographic Presence
42 Creative Biolabs: Company Snapshot
43 Creative Biolabs: SWOT Analysis
44 Creative Biolabs: Geographic Presence
45 Novavax: Company Snapshot
46 Novavax: SWOT Analysis
47 Novavax: Geographic Presence
48 Sanofi: Company Snapshot
49 Sanofi: Swot Analysis
50 Sanofi: Geographic Presence
51 AstraZeneca: Company Snapshot
52 AstraZeneca: SWOT Analysis
53 AstraZeneca: Geographic Presence
54 EVONIK: Company Snapshot
55 EVONIK: SWOT Analysis
56 EVONIK: Geographic Presence
57 Merck: Company Snapshot
58 Merck: SWOT Analysis
59 Merck: Geographic Presence
60 Sigma-Aldrich: Company Snapshot
61 Sigma-Aldrich: SWOT Analysis
62 Sigma-Aldrich: Geographic Presence
63 SK Bioscience.: Company Snapshot
64 SK Bioscience.: SWOT Analysis
65 SK Bioscience.: Geographic Presence
66 Precision NanoSystems: Company Snapshot
67 Precision NanoSystems: SWOT Analysis
68 Precision NanoSystems: Geographic Presence
69 Other Companies: Company Snapshot
70 Other Companies: SWOT Analysis
71 Other Companies: Geographic Presence
The Global Biomaterial-based Vaccines Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Biomaterial-based Vaccines Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
